Summary
Boston Scientific Corporation (BSX) reported its financial results for the second quarter ended June 29, 2010. The company demonstrated solid revenue performance, driven by continued growth in its key product segments. Management's discussion and analysis likely highlight strategies to capitalize on these trends and manage operational efficiencies. Investors should pay close attention to the company's ability to maintain this growth trajectory and manage its debt obligations effectively. The filing also provides insights into the company's liquidity position and its strategies for managing market risks, which are crucial for understanding the overall financial health and future prospects of Boston Scientific.
Financial Highlights
47 data pointsBeta
Financial Statements
Beta
| Revenue | $1.93B |
| Cost of Revenue | $654.00M |
| Gross Profit | $1.27B |
| SG&A Expenses | $634.00M |
| Operating Expenses | $1.04B |
| Operating Income | $231.00M |
| Interest Expense | $103.00M |
| Net Income | $98.00M |
| EPS (Basic) | $0.06 |
| EPS (Diluted) | $0.06 |
| Shares Outstanding (Basic) | 1.52B |
| Shares Outstanding (Diluted) | 1.53B |
Key Highlights
- 1Revenue growth in key business segments, indicating strong market demand for BSX's products.
- 2Analysis of operational performance, likely detailing factors contributing to revenue and profitability.
- 3Disclosure of financial condition, including balance sheet items and cash flow generation.
- 4Management's commentary on market risks and how the company plans to mitigate them.
- 5Information on legal proceedings, which could represent potential liabilities.
- 6Updates on risk factors that could impact the company's future performance.